Zilia Reaches Milestone of 1,000 Patients Enrolled in Clinical Studies

Quebec City, January 14, 2025 – Zilia has reached a significant milestone with over 1,000 patients now enrolled in clinical studies using its Zilia Ocular platform – a breakthrough technology that non-invasively assesses oxygen saturation and other biomarkers in the eye.

Zilia Ocular platform in clinical use.

This achievement stems from collaborations with world-class research institutions, including the University of Houston College of Optometry, the University of Montreal School of Optometry, and Kagawa University Faculty of Medicine. These partnerships have accelerated the development and validation of Zilia’s innovative technology.

“Reaching this milestone marks a pivotal moment in our mission to transform eye care,” said Patrick Sauvageau, CEO of Zilia. “The enthusiasm with which leading ophthalmology and optometry research centers have integrated the Zilia Ocular in their work, and the exciting data that stems out of it, show the great potential and value of our technology”

The Zilia Ocular platform is designed to address a critical unmet need in eye care by bridging the gap in ocular metabolic assessment. Unlike traditional diagnostic tools, which offer limited metabolic data, Zilia Ocular delivers real-time measurements of oxygen saturation. This technology has the potential to provide clinicians with groundbreaking insights into disease progression and treatment efficacy for a range of ocular conditions, such as glaucoma and diabetic retinopathy​​​​.

About Zilia

Zilia is a medical technology company developing a groundbreaking platform to non-invasively measure biomarkers in the eye, with an initial focus on ocular oximetry. By integrating advanced photonics and artificial intelligence, Zilia’s first-of-kind technology is intended to leverage the eye’s optical properties and its direct connections to the vascular system and the brain, capturing critical information on ocular and overall health.

More on our Blog